Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 13/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | EGFR | P00533 | 3/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.44 |
| ▸ | KDR | P35968 | 3/20 | 0.44 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25754350 | 0.76 | IDH1 (0.49) | IDH1MEN1MAPTHTTKMT2A | |
| SCHEMBL23846391 | 0.75 | IDH1 (0.51) | IDH1MEN1MAPTHTTKMT2A | |
| SCHEMBL23846383 | 0.74 | IDH1 (0.48) | IDH1MEN1MAPTHTTKMT2A | |
| SCHEMBL23846621 | 0.74 | MEN1 (0.54) | IDH1MEN1MAPTHTTKMT2A | |
| SCHEMBL25754345 | 0.73 | IDH1 (0.55) | IDH1MEN1MAPTHTTKMT2A | |
| SCHEMBL23846631 | 0.73 | IDH1 (0.46) | IDH1MAPTALDH1A1 | |
| SCHEMBL23840305 | 0.73 | SMN1; SMN2 (0.49) | IDH1MEN1MAPTHTTKMT2A | |
| SCHEMBL23846563 | 0.72 | NPC1 (0.69) | MEN1MAPTHTTKMT2AALDH1A1 | |
| SCHEMBL25755372 | 0.72 | NPC1 (0.51) | IDH1MEN1MAPTHTTKMT2A | |
| SCHEMBL25754353 | 0.71 | ABL1 (0.56) | IDH1MEN1MAPTHTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | AMATHUS THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | AMATHUS THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | US | disclosed |
| WO-2021188880-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | AMATHUS THERAPEUTICS, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | TRAP1, PINK1, TP53BP1 | IDH1 442/4885MEN1 3902/4885MAPT 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.